In a model of melanoma metastasis to the lung, it was shown that only two or three doses of lipid nanoparticles containing a STING pathway agonist (STING-LNP) with an anti-PD-1 antibody, administered at two-day intervals, enable activation of the immune response and potentiate the effect of the anti-PD-1 antibody. This evidence concerns the gene STING1 and melanoma.